Mirae Asset Global Investments
JNCE

Mirae Asset Global Investments’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Mirae Asset Global Investments’s Portfolio JNCE Stock Details JNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-27,327
Closed -$64K – 2641
2022
Q3 		$64K Buy
+27,327
New +$96.8K ﹤0.01% 2562

Other funds holding JNCE

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Mirae Asset Global Investments's JNCE Position: Q4 2022 in Review

Mirae Asset Global Investments sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q4 2022, closing a stake of 27,327 shares — an estimated $64K sold.

Mirae Asset Global Investments first reported a position in JNCE in Q3 2022 and held it in 1 quarter. The position peaked at $64K in Q3 2022. 85 funds tracked by Wall St. Rank hold JNCE as of Q4 2022.

  • Mirae Asset Global Investments reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Mirae Asset Global Investments sold 27,327 Jounce Therapeutics, Inc. Common Stock shares in Q4 2022, an estimated $64K.
  • Mirae Asset Global Investments first reported a position in Jounce Therapeutics, Inc. Common Stock in Q3 2022 and held it in 1 quarter.
  • Mirae Asset Global Investments's Jounce Therapeutics, Inc. Common Stock position peaked at $64K in Q3 2022.
  • 85 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q4 2022.

Based on Mirae Asset Global Investments's 13F filing for Q4 2022, filed 9 Feb 2023.